No registrations found.
ID
Source
Brief title
Health condition
Vetoplosbare vitamine deficientie, carcinoid tumor, acromegalie
Liposoluble vitamin deficiency, carcinoid tumour, acromegaly
Sponsors and support
Universitair Medisch Centrum Groningen
9700 RB Groningen
the Netherlands
Universitair Medisch Centrum Groningen
9700 RB Groningen
the Netherlands
Intervention
Outcome measures
Primary outcome
1. Liposoluble vitamins;
2. Relevant lipid components;
3. Relevant biochemical investigations to measure effects of possible vitamin deficiency, including calcium levels, PTH and coagulation.
Secondary outcome
N/A
Background summary
This is a cross-sectional explorative cohort study in patients receiving long-term octreotide treatment (longer than 18 months) for acromegaly or a carcinoid tumour. Patients will be investigated for vitamin-status at one time point. With this study we hope to get insight into the frequency and severity of deficiency of liposoluble vitamins in patients receiving long-term octreotide therapy. This will contribute to the early recognition and suppletion of (sub)clinical deficiencies thus improving patient’s health.
Single-center studie in Groningen, the Netherlands
Study objective
There is some evidence pointing towards a risk liposoluble vitamin deficiency in patients receiving long-term octreotide treatment. This is becoming clear only recently as there are now patients using this drug since it became available. Groups especially using octreotide are acormegaly patients and patients with carcinoid, who have as additional reason for vitamin deficiency the fact that often a part of the small bowel is resected. However, vitamin status is not routinely assessed in these patients, even though vitamin deficiency can seriously affect quality of life.
Study design
This investigation will be done by blood analysis at one time point.
Intervention
N/A
Postbus 30.001
H.B. Fiebrich
Groningen 9700 RB
The Netherlands
+31 (0)50-36161616
h.b.fiebrich@int.umcg.nl
Postbus 30.001
H.B. Fiebrich
Groningen 9700 RB
The Netherlands
+31 (0)50-36161616
h.b.fiebrich@int.umcg.nl
Inclusion criteria
Patients are eligible when they have used octreotide for at least 18 months. Patients must be 18 years or older and must be willing to give written informed consent.
Exclusion criteria
No informed consent, age less then 18 years.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1633 |
| NTR-old | NTR1730 |
| Other | MEC Groningen : 2008/286 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |